BR9608897A - DNA fusion polypeptide construction of recombinant dna cell transformed with the fungal or mammalian plant dna process to select compounds capable of being linked to a member of the selected compound insect steroid receptor superfamily using said agricultural or pharmaceutical composition process use of the compound peptide process or polypeptide - Google Patents

DNA fusion polypeptide construction of recombinant dna cell transformed with the fungal or mammalian plant dna process to select compounds capable of being linked to a member of the selected compound insect steroid receptor superfamily using said agricultural or pharmaceutical composition process use of the compound peptide process or polypeptide

Info

Publication number
BR9608897A
BR9608897A BR9608897A BR9608897A BR9608897A BR 9608897 A BR9608897 A BR 9608897A BR 9608897 A BR9608897 A BR 9608897A BR 9608897 A BR9608897 A BR 9608897A BR 9608897 A BR9608897 A BR 9608897A
Authority
BR
Brazil
Prior art keywords
dna
polypeptide
fungal
agricultural
linked
Prior art date
Application number
BR9608897A
Other languages
Portuguese (pt)
Inventor
Alberto Martinez
Andrew James Greenland
Ian Jepson
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9510759.5A external-priority patent/GB9510759D0/en
Priority claimed from GBGB9513882.2A external-priority patent/GB9513882D0/en
Priority claimed from GBGB9517316.7A external-priority patent/GB9517316D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Priority claimed from PCT/GB1996/001195 external-priority patent/WO1996037609A1/en
Publication of BR9608897A publication Critical patent/BR9608897A/en

Links

BR9608897A 1995-05-26 1996-05-20 DNA fusion polypeptide construction of recombinant dna cell transformed with the fungal or mammalian plant dna process to select compounds capable of being linked to a member of the selected compound insect steroid receptor superfamily using said agricultural or pharmaceutical composition process use of the compound peptide process or polypeptide BR9608897A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9510759.5A GB9510759D0 (en) 1995-05-26 1995-05-26 A gene switch
GBGB9513882.2A GB9513882D0 (en) 1995-07-07 1995-07-07 A gene switch
GBGB9517316.7A GB9517316D0 (en) 1995-08-24 1995-08-24 A gene switch
PCT/GB1996/001195 WO1996037609A1 (en) 1995-05-26 1996-05-20 A gene switch comprising an ecdysone receptor

Publications (1)

Publication Number Publication Date
BR9608897A true BR9608897A (en) 1999-06-29

Family

ID=27267742

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9608897A BR9608897A (en) 1995-05-26 1996-05-20 DNA fusion polypeptide construction of recombinant dna cell transformed with the fungal or mammalian plant dna process to select compounds capable of being linked to a member of the selected compound insect steroid receptor superfamily using said agricultural or pharmaceutical composition process use of the compound peptide process or polypeptide

Country Status (1)

Country Link
BR (1) BR9608897A (en)

Similar Documents

Publication Publication Date Title
Israel et al. Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo
Reagan Expression cloning of an insect diuretic hormone receptor. A member of the calcitonin/secretin receptor family.
CA1341030C (en) Protein active in humoral hypercalcemia of malignancy-pthrp
CA2053275A1 (en) Fibroblast Growth Factor Conjugates
JP2008133295A (en) Modified peptide pharmaceutical
PT835266E (en) MODIFIED / CHEMICAL SURFACES AND ITS USE
CA2127362A1 (en) Expression and Purification of Recombinant Soluble Tissue Factor
KR20010074461A (en) Oxidized thymosin beta 4
DE69636437D1 (en) LIGAND POLYPEPTIDE FOR HYPOPHYSE G PROTEIN COUPLED RECEPTOR PROTEIN, THEIR PREPARATION AND APPLICATION
BR9301420A (en) NECROSIS FACTOR MUTEIN, DNA SEQUENCE, VECTOR, HOST CELL, COMPOUND, PROCESS FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION AND USE
BR9606437A (en) Polynucleotide and purified polypeptide in the host cell vector processes to produce mdc to produce an mdc polypeptide analog to modulate leukocyte chemotaxis in a mammalian host to alleviate an inflammatory cleavage in a patient and to identify an anti-hybridoma cell line antibody chemical compound polyclonal serum and pharmaceutical composition and use of the composition
DE69803565D1 (en) ANTIVIRAL PHARMACEUTICAL COMPOSITIONS CONTAINING GLYCYRRHIZINIC ACID AND AT LEAST ONE PROTEIN WITH ANTIVIRAL EFFECTIVENESS
BR9608897A (en) DNA fusion polypeptide construction of recombinant dna cell transformed with the fungal or mammalian plant dna process to select compounds capable of being linked to a member of the selected compound insect steroid receptor superfamily using said agricultural or pharmaceutical composition process use of the compound peptide process or polypeptide
GÄDE Structure–function studies on hypertrehalosaemic and adipokinetic hormones: activity of naturally occurring analogues and some N‐and C‐terminal modified analogues
BR9809855B1 (en) fungicidal mixture, process for weed control, use of compost, and composition.
EP0992584A3 (en) Purified mammalian FLT3 ligands and agonists and antagonists thereof
CA2083837A1 (en) Recombinant dna coding for a novel protein having .beta.-1,3 glucanase activity, bacteria containing this dna, transformed plant cells and plants
Regan et al. Identification of the subunit-binding site of alpha 2-adrenergic receptors using [3H] phenoxybenzamine.
ATE253636T1 (en) POLYPEPTIDES INTERACTING WITH SMAD AND USES THEREOF
BR9507451A (en) Pharmaceutical composition use of an amount of (i) a standardized antigen together with an amount of (ii) a polypeptide and product containing an amount of (i) a standardized antigen together with an amount of (ii) a polypeptide
NZ334714A (en) Liver proteins as agents against autoimmune diseases
US7485622B2 (en) Paralytic peptide for use in neuromuscular therapy
BR9612013A (en) Derived from 2-(0-(pyrimidin)-4-yl)-phenyl-acetic acid or a salt or n-oxide thereof and use of the same composition suitable for the control of harmful fungi and animal pests and processes for its preparation and for control of harmful fungi and animal pests
BR9912814A (en) Chimeric polypeptides allowing the expression of harmful plant proteins
CH670451A5 (en)

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements